公开(公告)号：US20200276255A1

公开(公告)日：2020-09-03

申请号：US16803968

申请日：2020-02-27

Applicant: NINE B CO., LTD. ,  AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Seon-Yong JEONG ,  Eunkuk PARK

IPC: A61K36/185 ,  A61K36/40 ,  A61P5/30

Abstract: The present invention provides a pharmaceutical composition and health functional food composition for preventing or treating female menopausal disease including extract of Ribes fasciculatum leaves as an active ingredient, and a pharmaceutical composition and health functional food composition for preventing or treating female menopausal disease including an extract of Cornus officinalis and extract of Ribes fasciculatum leaves as active ingredients.

公开(公告)号：US20200165674A1

公开(公告)日：2020-05-28

申请号：US16612031

申请日：2018-05-10

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Seon-Yong JEONG ,  Eunkuk PARK ,  Gijeong KIM

IPC: C12Q1/6883 ,  G01N33/68

Abstract: A COTL1 gene or protein maintains and regulates the homeostasis of hematopoietic stem cells. A method of diagnosis and treatment of blood-related disease caused either by abnormalities in the homeostasis of hematopoietic stem cells, which result from a mutation in the COTL1 gene or a decrease in the expression of the COTL1 protein, or by an imbalance between the differentiation or proliferation and damage or death of hematopoietic stem cells, or by abnormalities in mitochondrial homeostasis. The COTL1 gene or protein plays an important role in regulating mitochondrial morphology, and when it is knocked down, the number of hematopoietic stem cells decreases.

公开(公告)号：US20170252363A1

公开(公告)日：2017-09-07

申请号：US15447056

申请日：2017-03-01

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Seon-Yong JEONG ,  Si Young YANG ,  Eun Kuk PARK ,  Jeong Hyun KIM ,  Mun-Chang KIM

IPC: A61K31/7048 ,  A23L33/10

CPC classification number: A61K31/7048 ,  A23L33/10 ,  A23V2002/00

Abstract: Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.